Goldman Buys FGI to Reshape Lending

Goldman Sachs just snapped up FGI Worldwide. Why? FGI's 25-year track record in asset lending and risk mitigation. Now, with Goldman’s backing, they're poised for explosive growth. But what does this mean for their clients and the market at large? Could this shift redefine the game in asset lending?

STERIS missed EPS estimates, but guess what? They're raising guidance. Revenue hit $1.59B, right on target. Yet, EPS fell short at $2.83. Operating margin took a dive too. So why the upbeat forecast? Could their new products be the secret weapon? Something's brewing. Curious? Dig deeper.

Lilly hits pause on its obesity campaign in India. The reason? Regulatory pushback. India's drug watchdog warns of indirect drug promotion. Lilly seeks clarity but gets tangled in red tape. The obesity market's booming, yet Lilly's campaign stalls. What's the future for pharma marketing in India's complex landscape?